Introduction
Chronic lymphocytic leukemia (B-CLL) is a malignancy of a mantle zone-based subpopulation of anergic, self-reactive CD5 + B cells devoted to the production of polyreactive natural autoantibodies.
1,2 B-CLL is characterized by the accumulation of long-lived, non-dividing CD5 + B cells in G 0 of the cell cycle. Although B-CLL cells are long-lived in vivo, they undergo rapid and spontaneous apoptosis when cultured in vitro. 3 A variety of factors prevent spontaneous apoptosis of cultured B-CLL cells; these include IL-2, IL-4, IL-6, IL-8, IFN-␣, IFN-␥, G-CSF, CD40 ligation, CD6 ligation and bone marrowderived stromal cells. [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] The lipid-soluble, gaseous free radical nitric oxide (NO) is an important regulator of apoptosis, and the viability of cultured B-CLL cells is dependent on the autocrine production of NO. 17 B-CLL cell apoptosis is regulated by caspases that promote apoptosis and by factors such as bcl-2 which inhibit apoptosis. [18] [19] [20] [21] NO maintains bcl-2 levels in cultured mouse splenic B cells and prevents their spontaneous apoptosis. 22 NO also binds to and inhibits the active site of many of the human caspase family members. [23] [24] [25] In B cells, NO reversibly modifies the active site cysteine of caspase-3 and inhibits its activity; fas-mediated signaling denitrosylates caspase-3 and initiates its activation and apoptosis of the cell. 26 NO is produced by three different nitric oxide synthases (NOS) in humans. 27, 28 Two of these isoforms, NOS1 and NOS3 produce low levels of NO and are constitutively active. In human cells, inducible NOS (NOS2) produces NO in response to cytokines including IL-1, IL-4, IL-6, TNF-␣, IFN-␣ and IFN-␥. 29 As discussed, IL-4, IL-6, IFN-␣ and IFN-␥ also prevent spontaneous apoptosis of cultured B-CLL cells; this suggests a possible link between the inhibition of spontaneous apoptosis of cultured B-CLL cells and NO production. Therefore, we performed this study to determine whether cytokines that prevent spontaneous in vitro apoptosis of B-CLL cells promote B-CLL cell NOS2 expression and NO production. An understanding of B-CLL cell NO production may identify new strategies for the treatment of B-CLL.
Materials and methods

Antibodies
The anti-NOS2 antibody, 1E8-B8, was generously provided by Robert Webber (R&D Antibodies, Berkeley, CA, USA). The anti-NOS3 antibody, clone 33 was obtained from Transduction Laboratories (Lexington, KY, USA). Anti-CD3-FITC (clone UCHT1), anti-CD5-PE (clone UCHT2), anti-CD19-FITC (clone HIB19), anti-CD19-CyChrome (clone B43) and fluorochromelabeled isotype control antibodies were purchased from Pharmingen (San Diego, CA, USA). For some experiments, anti-CD19-FITC (clone J4.119) was purchased from Immunotech (Marseille, France). Anti-CD14-PE (clone TUK4) was purchased from DAKO (Carpinteria, CA, USA). All antibodies were titered and used at saturating concentrations for the immunoblots and phenotypes.
Cytokines and NOS2 cofactors, substrates and inhibitors
IL-2, IL-4, IL-6, IL-8, interferon gamma (IFN-␥), granulocyte colony-stimulating factor (G-CSF), nerve growth factor (NGF) and tumor necrosis factor alpha (TNF-␣) were purchased from R&D Systems (Minneapolis, MN, USA). Interferon alpha 2a (IFN-␣) (Roferon-A) was purchased from Roche Laboratories (Nutley, NJ, USA). L-sepiapterin was purchased from Alexis Biochemicals (San Diego, CA, USA); L-arginine was purchased from Sigma (St Louis, MO, USA); N-hydroxy-Larginine was purchased from Cayman Chemical (Ann Arbor, MI, USA).
B-CLL cell isolation
Peripheral blood mononuclear cells (PBMC) were isolated from B-CLL patient peripheral blood samples using FicollHypaque density gradients. 31 For some experiments, B-CLL cells were enriched by depletion of T cells and monocytes using magnetic beads coupled with anti-CD2 and anti-CD14 antibodies, respectively, according to the manufacturer's instructions (Dynal, Lake Success, NY, USA) or B-CLL cells were enriched by depletion of T cells and monocytes using RosetteSep Human B Cell Enrichment Cocktail (Vancouver, British Columbia, Canada), according to the manufacturer's instructions. The purity of these T cell-and monocytedepleted B-CLL preparations (n = 75) was determined by flow cytometry and on average ± s.e.m. were 91. 4 
Normal B cell isolation
PBMC were isolated from normal individuals using FicollHypaque density gradients. 31 B cells were enriched using magnetic beads coupled with an anti-CD19 antibody and DETACHaBEAD CD19 according to the manufacturer's instructions (Dynal). The purity of these B cell preparations (n = 5) was determined by flow cytometry and on average ± s.e.m. were 24. 
B-CLL cell culture
0.25 × 10 6 , 3 × 10 6 or 15 × 10 6 B-CLL cells were cultured in 96-well (MTS viability assays), 24-well (NO x assays) or sixwell (NOS enzyme assays, NOS2 Western blots, NOS2 mRNA RT-PCR) tissue culture plates in 0.1 ml of L-arginine-free Hybridoma SFM (Gibco, Long Island, NY, USA), or in 1 ml or 5 ml of Hybridoma SFM, respectively, at 37°C, 5% CO 2 in air as described. 32 
NO synthase enzyme activity measurement
B-CLL cells were lysed by three freeze-thaws in buffer containing distilled water, 100 M phenylmethylsulfonyl fluoride, Leukemia 5 g/ml aprotinin, 1 g/ml chymostatin, 5 g/ml pepstatin A and 1 mM 4-(2-Aminoethyl)-benzenesulfonyl fluoride (Sigma). The soluble fraction was collected following centrifugation at 4°C for 10 min at 16 000 g. Protein concentration was determined using the Bio-Rad Protein Assay (Bio-Rad, Hercules, CA, USA). NOS enzyme activity was measured as the conversion of L-arginine to L-citrulline as described. 33 Briefly, B-CLL cell lysates (30 
NOS2 and NOS3 immunoblots
B-CLL cells, DLD-1 cells treated with human recombinant IFN-␥ (100 U/ml), TNF-␣ (100 U/ml), IL-1␤ (0.5 ng/ml) and IL-6 (200 U/ml) for 3 days 34 and EA.hy926 cells were lysed and a soluble protein extract was prepared as described for the NO synthase enzyme activity measurements. For each sample, 30 g of protein was separated by electrophoresis on 10% polyacrylamide gels and electrophoretically transferred to nitrocellulose filters. NOS2 and NOS3 on nitrocellulose filters were detected using mabs 1E8-B8 and clone 33, respectively, and indirect immunoperoxidase staining using horseradish peroxidase-conjugated goat anti-mouse IgG antibodies (Jackson ImmunoResearch Laboratories, West Grove, PA, USA). Protein bands were visualized by incubation with ECL chemiluminescence reagent (Amersham, Buckinghamshire, UK) followed by exposure to film. For each sample, an integrated density value (IDV) for the band corresponding to NOS2 was determined with a densitometer (Alpha Innotech, San Leandro, CA, USA) and normalized for each patient sample by comparison to the IDV for B-CLL cells from the same patient not treated with cytokine.
NOS2 and NOS3 mRNA isolation and detection by non-quantitative RT-PCR
Total RNA was isolated by the method of Chomczynski and Sacchi. 35 Total RNA from DLD-1 cells treated with human recombinant IFN-␥ (100 U/ml), TNF-␣ (100 U/ml), IL-1␤ (0.5 ng/ml) and IL-6 (200 U/ml) for 3 days was used as a positive control for NOS2. 34 Total RNA from untreated EA.hy926 cells was used as a positive control for NOS3. One mg of RNA was reverse transcribed with random hexamers and murine leukemia virus reverse transcriptase (Perkin Elmer, Branchburg, NJ, USA) for 30 min at 42°C, and the reaction stopped by heating at 90°C for 5 min. The cDNA samples were divided into three 10 l aliquots and each aliquot was added to 40 l of PCR reaction mixture containing a final concentration of 200 nM of either NOS2, NOS3 or as a positive control glyceraldehyde-3-phosphate dehydrogenase (GAPDH) primer pairs with 200 M of each dNTP, 50 mM KCl, 10 mM TrisHCl pH 8.3, 4 mM MgCl 2 and 1.25 U of Taq DNA polymerase Leukemia (Perkin Elmer). The samples were heated at 92°C for 3 min, followed by 40 cycles at 92°C for 30 s, 60°C for 1 min and 72°C for 1 min, and then a final 7 min at 72°C. The PCR products were analyzed on a 3% agarose gel and visualized by ethidium bromide staining. For NOS2 detection, the primers were 5Ј-CCT GAG CTC TTC GAA ATC C-3Ј (sense) and 5Ј-AGG ATG TTG TAG CGC TGG AC-3Ј (anti-sense) and yielded an expected product of 229 bp. For NOS3 detection, the primers were 5Ј-GTG ATG GCG AAG CGA GTG AAG-3Ј (sense) and 5Ј-CCG AGC CCG AAC ACA CAG AAC-3Ј (antisense) and yielded an expected product of 394 bp. For GAPDH detection, the primers were 5Ј-CTA CTG GCG CTG CCA AGG CTG T-3Ј (sense) and 5Ј-GCC ATG AGG TCC ACC ACC GTG T-3Ј (anti-sense) and yielded an expected product of 390 bp.
Quantitation of NOS2 mRNA using real-time RT-PCR
Quantitative NOS2 and GAPDH mRNA determinations were performed on total RNA samples from freshly isolated and cytokine-treated B-CLL cell samples. For quantitative PCR, RNA was isolated from B-CLL cells using the RNeasy Mini RNA isolation kit (Qiagen, Valencia, CA, USA). RNA samples were DNase-treated (Qiagen) during RNA isolation. 0.5 g RNA samples were initially converted to cDNA using murine leukemia virus reverse transcriptase as outlined above for nonquantitative RT-PCR. PCR analysis of 3 L of cDNA product was performed in a LightCycler instrument from Roche (Indianapolis, IN, USA) with the LightCycler-FastStart DNA Master Hybridization Probes kit (Roche), HPLC-purified primers (Gibco-BRL and Integrated DNA Technologies, Coralville, IA, USA) at a concentration of 0.5 M each, SYBR Green I (0.2 ×) (Molecular Probes, Eugene, OR, USA) and 5 mM Mg for NOS2 and GAPDH reactions. For each RNA sample, duplicate NOS2 and GAPDH determinations were performed and the results averaged. The samples were heated at 95°C for 10 min, followed by 40 cycles at 95°C for 10 s, 62°C for 5 s and 72°C for 15 s. The interrogation temperature for SYBR Green I fluorescence was 85°C. Following PCR, a melting curve from 62°C to 95°C at 0.1°C/s intervals with continuous fluorescence measurements was determined for each sample. For NOS2 detection, the primers were 5Ј-GGA TAA GTA CAG GCT GAG CTG CC-3Ј (sense) and 5Ј-GTA GAT TCT GCC GAG ATT TGA GCC-3Ј (anti-sense). For GAPDH detection, the primers were 5Ј-CTA CTG GCG CTG CCA AGG-3Ј (sense) and 5Ј-GCC ATG AGG TCC ACC ACC-3Ј (anti-sense). Standard curves for NOS2 and GAPDH mRNA quantitation were created by serial dilution of a known quantity of the NOS2 and GAPDH PCR products. The specificity of the PCR reaction was confirmed by analysis of some samples by gel electrophoresis.
Nitrite and nitrate quantitation
The concentrations of nitrite and nitrate in the media of B-CLL cells cultured for 24 h in media with and without cytokines were determined. Nitrite was measured using a modified Griess assay. 36 Nitrate was measured as nitrite following reduction by Aspergillus nitrate reductase (Boehringer Mannheim, Indianapolis, IN, USA) as previously described, 37 and the concentration of nitrate was determined by subtracting nitrite concentration before reduction from nitrite concentration after reduction. The concentrations of nitrite and nitrate in media samples incubated in parallel without B-CLL cells were determined and subtracted as background from nitrite and nitrate concentrations from media cocultured with B-CLL cells. Nitrite and nitrate concentrations were summed and expressed as total NO x .
MTS viability assay
The percentage of viable B-CLL cells following culture for 3 days in arginine-free Hybridoma SFM media containing L-NMMA (0.125 mM to 8 mM) was determined using the tetrazolium compound 3- 
Statistical analyses
Non-parametric statistics were used because the results of the NOS enzyme activity determinations, immunoblot IDVs, mRNA levels, NO x levels and cytotoxicity assays were not normally distributed. Comparisons of PBMC NOS enzyme activity between normal individuals and B-CLL patients was performed using the Mann-Whitney U test. Comparisons of NOS enzyme activity determinations, immunoblot IDVs, mRNA levels, NO x levels of B-CLL cells cultured either with or without cytokines, and L-NMMA-induced B-CLL cell cytotoxicity either with or without cytokines were performed using the Wilcoxon signed-rank test.
Results
Analysis of B-CLL cell NOS2 enzyme activity, protein expression and mRNA expression
Other investigators have determined that B-CLL cells express NOS2 enzyme activity. 17 We also determined whether B-CLL cells expressed NOS enzyme activity as measured by the conversion of 14 C-L-arginine to 14 C-L-citrulline. We found that B-CLL cells expressed high levels of NOS enzyme activity as compared to PBMC from normal individuals (Figure 1a ). Purified B cells from normal individuals (n = 5) expressed comparable levels of NOS enzyme activity as PBMC from normal individuals (data not shown). Because both NOS2 and NOS3 have been detected in human B cells, 38, 39 we determined whether B-CLL cells expressed NOS2 and/or NOS3 mRNA and protein. Non-quantitative RT/PCR analysis of mRNA from B-CLL cells indicated that 12 of 13 samples expressed NOS2 mRNA and none of 13 samples expressed NOS3 mRNA (Figure 1b) . By comparison, RT/PCR of mRNA from PBMC from normal individuals indicated that no samples expressed NOS2 or NOS3 mRNA (n = 12). In addition, immunoblots of protein from B-CLL cells indicated that five of eight samples expressed NOS2 and none of eight samples expressed NOS3 
NO production in B-CLL cells
In contrast to the results of Zhao et al, 17 we were unable to detect increased concentrations of nitrite or nitrate (NO x ), as surrogate markers of NO production, in the media of cultured B-CLL cells. We were unable to detect increased nitrite concentrations using a modified Griess reaction assay system 36 in the media of B-CLL cells cultured at a ratio of 3 × 10 6 B-CLL cells/ml of culture media for 3 days (data not shown). Likewise, we were unable to detect nitrate in the media of B-CLL cells cultured for 3 days using a nitrate reductase-based assay system 37 (data not shown). In addition, we used several methods to improve production of NO x in the media of cultured B-CLL cells and we were unable to detect increased NO x ; we cultured B-CLL cells at higher cell densities (6-30 × 10 6 cells/ml), for shorter and longer periods of time (1, 3 or 5 days) and in different media (DMEM/10% FCS and RPMI/10% FCS) (data not shown). We also cultured B-CLL cells in increased amounts of arginine (1 to 10 mM) and/or sepiapterin (100 M), (a precursor for the NOS2 cofactor tetrahydrobiopterin) (data not shown). Furthermore, we did not see decreases in NOS2 enzyme activity measured in B-CLL cell lysates in the absence of exogenous tetrahydrobiopterin (data not shown) suggesting that the availability of tetrahydrobiopterin was not limiting B-CLL NOS2 enzyme activity. We also did not detect increased concentrations of NO x in the media of B-CLL cells incubated for 4 h in Hanks' balanced salt solution (HBSS) or 0.9% saline (to reduce NO x background) and measured on a chemiluminescent NO detector (data not shown). Finally, we did not detect NO x in the media of B-CLL cells cultured with N-hydroxy-L-arginine (16 M to 2000 M), an arginase inhibitor 40 and intermediate in the metabolism of arginine to NO (data not shown).
Cytokine induction of B-CLL cell NOS2 enzyme activity and protein expression
Several cytokines, including IL-2, IL-4, IL-6, IL-8, IFN-␣, IFN-␥ and G-CSF have been shown to prevent B-CLL cell apoptosis and death. [4] [5] [6] [8] [9] [10] [11] [12] [13] [14] [15] NGF is an autocrine survival factor for memory B cells. 41 We tested whether IL-2, IL-4, IL-6, IL-8, IFN-␣, IFN-␥, NGF or G-CSF would induce B-CLL cell NOS2 enzyme activity following in vitro culture. As shown in Figure  2 Effect of IL-2, IL-4, IL-6, IL-8, IFN-␣, IFN-␥, G-CSF and NGF on B-CLL cell NOS2 enzyme activity. PBMC were isolated from the peripheral blood of patients with B-CLL and enriched by depletion of T cells and monocytes as described in Materials and methods. B-CLL cells were cultured for 24 h in Hybridoma SFM containing either no cytokine, IL-2 (100 ng/ml), IL-4 (5 ng/ml), IL-6 (100 ng/ml), IL-8 (100 ng/ml), IFN-␣ (500 units/ml), IFN-␥ (500 units/ml), G-CSF (500 units/ml) or NGF (100 ng/ml). B-CLL cells were harvested by centrifugation at 400 g for 5 min and NOS enzyme activity determined as the conversion of 14 C-L-arginine to 14 C-L-citrulline. Vertical lines represent 10th and 90th percentiles, and boxes represent 25th and 75th percentiles. The horizontal line in each plot represents the median (50th percentile), and the dot represents the mean for the data. The number of samples analyzed and the P value for Wilcoxon signedrank test comparisons of cytokine-treated vs non-cytokine-treated samples are presented in the figure. activity in IL-4-and IFN-␥-treated B-CLL cells was associated with significant increases in NOS2 protein expression as determined by Western blot (Figure 3 ). As shown in Figure 3 , nine of nine and seven of nine B-CLL cell samples cultured with IL-4 and IFN-␥, respectively, expressed increased levels of NOS2 by Western blot analysis as compared to B-CLL cell samples cultured in media without cytokines. The wide range of fold differences in B-CLL cell NOS2 expression following IL-4 and IFN-␥ treatment is likely reflective of the heterogeneous nature of B-CLL. [42] [43] [44] [45] Because previous studies have shown a correlation between B-CLL cell survival in culture and bcl-2 levels during culture with IL-4 9 and during culture in serum-free media, 32 the results shown in Figures 2 and 3 raise the possibility that a combination of factors including bcl-2 and NOS2 may modify B-CLL cell apoptosis during in vitro culture.
Time-course analysis of IL-4 and IFN-␥ induced B-CLL cell NOS2 mRNA production
To understand the mechanism of the increase in NOS enzyme activity and NOS2 protein expression associated with IL-4 and IFN-␥ treatment of B-CLL cells, we determined the effect of these cytokines on the expression of NOS2 mRNA in B-CLL cells (Figure 4) . We cultured freshly isolated B-CLL cells from five different patients with IL-4 or IFN-␥ and harvested the cells at 2, 4, 8 and 20 h following cytokine treatment and determined the quantity of NOS2 mRNA in these samples Figure 2 . B-CLL cells were cultured in Hybridoma SFM containing either no cytokine, IL-2 (100 ng/ml), IL-4 (5 ng/ml), IL-6 (100 ng/ml), IFN-␣ (500 units/ml), IFN-␥ (500 units/ml) or NGF (100 ng/ml) for 24 h. B-CLL cells were harvested as described in Figure 2 and analyzed by immunoblot with the NOS2 mab 1E8-B8. (a) A representative blot is shown. Median fold differences of integrated density values (IDV) for cytokine-treated NOS2 bands compared to non-cytokine-treated NOS2 bands, the number of samples analyzed and the P value for Wilcoxon signed-rank test comparisons of IDVs for cytokine-treated vs non-cytokine-treated samples are presented in the figure. The fold differences of IDVs for NOS2 bands of cytokine-treated compared to non-cytokine-treated samples are 3.9, 2.7, 1. Time-course analysis of NOS2 mRNA expression from B-CLL cells cultured with no cytokine, IL-4 or IFN-␥. B-CLL cells were isolated and enriched as described in Figure 2 . B-CLL cells were cultured in Hybridoma SFM containing either no cytokine, IL-4 (5 ng/ml) or IFN-␥ (500 units/ml) for 4, 8 or 20 h. Cultured B-CLL cells were harvested and NOS2 mRNA levels were determined by quantitative RT-PCR as described in Materials and methods. The data are expressed as median fold change from the time of isolation (0 h) of NOS2/GAPDH mRNA × 10 3 ratios (n = 4). P = non-significant for comparisons of cytokine-treated samples vs no cytokine at each time point.
Hybridoma SFM without cytokines was not statistically significant.
NO production in cytokine-treated B-CLL cells
We also determined whether cytokine treatment of B-CLL cells induced NO production. We cocultured B-CLL cells with IL-2, IL-4, IL-6, IL-8, IFN-␣, IFN-␥, NGF or G-CSF and measured nitrite and nitrate concentrations in the culture media. None of these cytokines induced NO x production (data not shown). We also cocultured B-CLL cells with IL-4, IFN-␣ or IFN-␥ and increased amounts of arginine (1 to 10 mM) and/or sepiaterin (100 M) for 1, 3 or 5 days. None of these culture conditions induced NO x production (data not shown).
Effect of IL-4 and IFN-␥ on NOS inhibitor-induced B-CLL cell cytotoxicity
To determine whether IL-4 and IFN-␥ induced NOS2 expression in B-CLL cells was associated with decreases in NOS2-inhibitor B-CLL cytotoxicity, we treated B-CLL cells (n = 6) with increasing concentrations of L-NMMA and with IL-4 and IFN-␥ for 3 days, and measured B-CLL cell cytotoxicity using an MTS assay ( Figure 5 ). Although modest, IL-4 and IFN-␥ significantly decreased L-NMMA-induced B-CLL cell cytotoxicity at high concentrations of L-NMMA (4 mM and 8 mM).
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Figure 5
Effect of IL-4 and IFN-␥ on NOS inhibitor-induced B-CLL cell cytotoxicity. B-CLL cells (n = 6 samples from six different patients) were isolated and enriched as described in Figure 2 . B-CLL cells were cultured in Hybridoma SFM without arginine and containing either no cytokine, IL-4 (5 ng/ml), IFN-␥ (500 units/ml) or IL-4 and IFN-␥ for 3 days. Cultured B-CLL cells were harvested and cytotoxicity determined using an MTS assay as described in Materials and methods. The data are expressed as mean cytotoxicity and the error bars represent s.e.m. For 4 mM L-NMMA, P = 0.0156, 0.0312 and 0.0156 for comparison of no cytokine treatment to IL-4, IFN-␥ and IL-4 and IFN-␥, respectively, using a one-tailed Wilcoxon signed-rank test. For 8 mM L-NMMA, P = 0.0156, 0.0781 and 0.0156, respectively. For all other comparisons, P = non-significant.
Discussion
NO is an important regulator of apoptosis in human B cells. 17, 26, 38 B-CLL is characterized by a failure of the CD5 + malignant B cells in this disease to undergo apoptosis and by the accumulation of long-lived malignant cells. 1 In this study, we found that B-CLL cells expressed NOS2. We also found that IL-4 and IFN-␥ increased B-CLL cell NOS2 enzyme activity and protein expression. IFN-␥, but not IL-4, increased NOS2 mRNA expression. We were unable to demonstrate increased concentrations of NO x in the media of B-CLL cell cultures and believe that NO produced by B-CLL cells was below the limit of detection (0.5 M) of our assays. Importantly, IL-4 and IFN-␥ decreased NOS inhibitor-induced B-CLL cell death. These studies suggest that IL-4 and IFN-␥ may be important regulators of NOS2 expression in B-CLL cells, and raise the possibility that IL-4 and IFN-␥ prevent B-CLL cell apoptosis by their effects on NOS2 expression.
The absence of the NO metabolites, nitrite and nitrate, in the media of cultured and cytokine-treated B-CLL cells may be due to several reasons. (1) One possibility is that our technique of measuring nitrite and nitrate was not sensitive enough. We believe that this is unlikely because we used a serum-free medium (Hybridoma SFM) that contains relatively low levels of nitrite and nitrate as compared to other available culture media such as RPMI plus fetal calf serum, and we used a chemiluminescent technique that is sensitive to small changes in the quantity of nitrite and nitrate in culture media.
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(2) The second possibility is that arginine availability to the NOS2 enzyme in B-CLL cells is limited or regulated. We assessed this possibility by adding high concentrations of arginine (10 mM) to B-CLL cell cultures, but did not detect nitrite or nitrate in B-CLL culture media. B-CLL cells can transport arginine and express the y + cationic amino acid transporter. 46 This raises the possibility that NOS2 is compartmentalized in B-CLL cells and arginine availability to this compartment is limited. For example, endothelial cells appear to regulate NOS3-mediated NO production by colocalization of the CAT1 amino acid transporter and arginosuccinate synthase and lyase with NOS3 in caveolae. 47, 48 Another possibility is that arginine availability to NOS2 in B-CLL cells is limited by other enzymes that metabolize arginine including arginase and arginine decarboxylase. 40 No studies have been performed to assess the expression of these enzymes in B-CLL cells. In the absence of arginine, NOS2 produces superoxide. 49, 50 However, we did not detect hydrogen peroxide or superoxide in B-CLL cells (data not shown), and this argues against the possibility that NO production in NOS2 expressing B-CLL cells is limited by the availability of arginine. (3) The third possibility is that B-CLL cells lack one of the important cofactors necessary for NOS2 activity. The NOS2 co-factor tetrahydrobiopterin has been shown to be rate-limiting for NOS2-mediated NO production in macrophages. 51 We believe that this is unlikely because sepiapterin, a tetrahydrobiopterin precursor, did not promote NO production in B-CLL cells and the elimination of tetrahydrobiopterin from our NOS enzyme assays did not effect the conversion of arginine to citrulline. (4) The fourth possibility is that NO is 'trapped' in B-CLL cells after its production by proteins or small molecules in the form of nitrosothiols or nitrotyrosines and is not released in the media. 52, 53 We are currently performing further experiments to address each of these possibilities and to explain the absence of nitrite and nitrate in the culture media of B-CLL cells.
Both IL-4 and IFN-␥ have been shown to induce NOS2 expression in other cell systems besides B-CLL. 29 IFN-␥ has been consistently shown to be an important inducer of NOS2 expression in several human cell types including macrophages and epithelial cells. 29, 54 The NOS2 promoter contains several interferon gamma activation sites (GAS elements), and IFN-␥ appears to regulate NOS2 expression primarily at the transcriptional level. 55 Alternatively, IL-4 has been shown to inhibit and induce NOS2 expression in macrophages. 56, 57 In human airway epithelial cells (HAEC), IL-4 and IFN-␥ act together to promote NOS2 expression. 54 In HAEC, IL-4 prolongs expression of NOS2 mRNA and sustained activation of STAT1 which binds to a GAS promoter element. IL-4 has also been shown to induce transcription factor STAT6 binding to a GAS element in the monocytic cell line THP-1 55, 58 and in the B cell line BL-2. 59 In B-CLL cells, STAT-1 is activated 60 and STAT-6 nuclear translocation is induced by IL-4. 61 Therefore, taken together, these studies suggest that constitutive and cytokine-induced NOS2 expression in B-CLL cells may be regulated by STAT-1, STAT-6 and NOS2 GAS promoter elements at the transcriptional level. Our results indicate an IFN-␥-mediated increase in NOS2 mRNA levels and indicate no changes in NOS2 mRNA levels in IL-4-treated B-CLL cells. The IFN-␥-mediated increase in NOS2 mRNA could be due to increased NOS2 transcription or due to decreases in the degradation rate of NOS2 mRNA. In contrast, the absence of a change in NOS2 mRNA levels in B-CLL cells treated with IL-4 suggests that a post-transcriptional mechanism mediates IL-4-induced increases in NOS2 protein expression. Such a post-transcriptional mechanism for IL-4-mediated increases in NOS2 expression has not been previously described to our knowledge.
In normal B cells, IL-4 and IFN-␥ have a dichotomous role in B cell activation and development. IL-4 induces B cell production of IgE and IgG 1 and increased expression of Fc⑀RII (CD23) and MHC class II. 62, 63 In contrast, IFN-␥ is an inhibitor of IgE and IgG 1 production in response to IL-4 and augments IgG 2a and IgG 3 class switching. 62, 63 In addition, IL-4 promotes B cell viability and proliferation in the context of T cell CD40L interactions with B cells. 64, 65 In cultured B-CLL cells, IL-4 increases or maintains bcl-2 levels. 4 In contrast, similar findings have not been reported for IFN-␥. Therefore, taken together with the results of our NOS2 mRNA studies, our findings on IL-4-and IFN-␥-mediated upregulation of NOS2 expression in B-CLL cells may be a mechanism that explains the ability of these two cytokines to prevent B-CLL cell apoptosis.
Our study supports other work that suggests IL-4 and IFN-␥ may be involved in the progression and pathogenesis of B-CLL. [66] [67] [68] [69] [70] [71] There is increased expression of both IL-4 and IFN-␥ in T cells from patients with B-CLL as compared to normal individuals [66] [67] [68] and increased expression of IL-4 in B-CLL cells. 68, 69 There are also increased cell surface receptors for IFN-␥ on B-CLL cells 66 and increased IFN-␥ receptor expression is associated with higher stage of disease in B-CLL patients. 70 The degree of inhibition of apoptosis by IFN-␥ was greater in cells from high-risk group patients compared to those in intermediate and good prognosis groups. 70 This suggests that the inhibitory effect on apoptosis correlates directly with the severity of B-CLL. Likewise, IL-4 therapy in patients with B-CLL resulted in a lymphocytosis and possible worsening of disease perhaps via the anti-apoptotic effects of IL-4. 71 Thus, our study has implications for the progression of B-CLL.
There are several other important implications of our study. Of greatest importance, because B-CLL cell viability may be dependent on NO production, NOS2 inhibition and NO quenching may be important therapeutic strategies in B-CLL. Our study may also have prognostic implications for patients with B-CLL. High-level NOS2 expression, similar to high level bcl-2 expression, may define subgroups of B-CLL patients with different prognoses. Studies are underway to test this hypothesis and to identify other markers that are associated with NOS2 expression in B-CLL cells. Together, these future studies will determine the role of NOS2 activation and NO production in the malignant behavior of B-CLL.
In summary, we found that B-CLL cells express inducible NOS. IL-4 and IFN-␥ induce B-CLL cell NOS2 expression. These studies have implications for the pathogenesis and treatment of B-CLL.
